Thomas Sidwell

6 Medical Device Makers Poised for Growth

People seems to be misunderstanding me about the my inclusion of ISRG. I think it is a great company with a great product with a very bright future ahead of it as the leader in its field. Period. I am not suggesting that ISRG is in trouble of plummeting, losing its edge, or going into bankruptcy. If this were true, we would have seen it by now. If you look at the title of the article, it says 6 medical Device Makers Poised for GROWTH. I am completely aware of the success that ISRG has had in this tough market. I am saying that they will do EVEN BETTER as credit loosens. Is anyone going to argue with me here? As for people saying I am unaware that management has stated they have been unaffected by the credit crunch, I simply respond that you have to take everything with a grain of salt. Look at Tomotherapy (TOMO). Their management said the exact same thing two quarters ago, then completely blew it this quarter. I am not saying they are in the same boat at all, but Enron sure had confident management as well, no? BABY is not in an earnings crisis either, on the contrary, they just blew out estimates, but I included them for similar reasons. I think that they will do better as credit loosens, which is the main point of this article.

Stereotaxis: when I said that i "do not know how many of the core abstracts truely relate to the Niobe system and how many of them are good" I simply meant that I have not read them all nor done a calculation to reach 90%. My neighbor, as "convenient" as it sounds, is a cardiologist, and we were talking about it and he prefers Sensei because he feels he has more control over the system. As for giving systems away, Moll has taken the view that it is more important to get them into doctors hands (who can then decide to use them or not) and try to get a dominate position in the market before going after seemingly short sighted reward systems. Does anyone want to comment on the fact that Stereotaxis has never come close to meeting its negative earnings estimate, already less optimistic than Hansen's (which in fairness has had its misses too and are negative as well). I will also say Stereotaxis balance sheet is not terrible.

I will continue to hear arguments about why Stereotaxis is better than Hansen, as there are certainly pros and cons of each system. Can anyone other than myself (and the market) say anything good about Hansen, or is this board full of pumpers and bashers? Also it is a waste of everyone's time to get these posts about ISRG, as I think I have very clearly addressed this issue.